Healthcare
Live Price
Offline$86.86
+5.81% today
Window Change
+23.59%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oruka Therapeutics, Inc. (ORKA) is a Healthcare stock with a market cap of $2.34B and listed on NASDAQ. The stock last traded around $86.86 and up 23.6% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +53.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +53.7%, free cash flow -52.4% with operating margin 0.0% and ROIC -25.8%. Stock Foundry combines ORKA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORKA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORKA Max Drawdown
-6.01%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ORKA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$19.3M
-94.7% YoY
Free Cash Flow
-$7.7M
+58.8% YoY
Revenue Growth
+0.0%
EPS Growth
+53.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -83K | -27K | -111K | -114K | -91K |
| Operating Income | -122M | -88M | -7M | -10M | -19M |
| EBITDA | -122M | -82M | -5M | -10M | -19M |
| Net Income | -105M | -84M | -5M | -10M | -19M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47M | 62M | 37M | 42M | 53M |
| Total Assets | 489M | 396M | 38M | 43M | 55M |
| Total Liabilities | 17M | 14M | 841K | 1M | 4M |
| Shareholder Equity | 472M | 382M | 37M | 42M | 51M |
| Total Debt | 2M | 968K | 280K | 383K | 483K |
| Net Debt | -45M | -61M | -37M | -42M | -53M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+58.8% YoY
Capital Expenditures
19K
+55.8% YoY
Free Cash Flow
8M
+58.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-25.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.